Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Oette

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Klinische Padiatrie|April 8, 2011
Terminally differentiated CD8 cells in HIV-infected children: HIV-GAG/POL specificity and IFN-γ productionD Delbeck, M Siepermann, O Feyen, et al.
AIDS (London, England)|July 14, 2000
Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study GroupJ K Rockstroh, F Bergmann, W Wiesel, et al.
Deutsche Medizinische Wochenschrift (1946)|April 26, 2007
[Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005]M Oette, R Kaiser, M Däumer, et al.
Gene Therapy|March 10, 2006
Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticlesT L Fink, P J Klepcyk, S M Oette, et al.
Spine|May 30, 2009
Treatment of spondylodiscitis in human immunodeficiency virus-infected patients: a comparison of conservative and operative therapyR Sobottke, K Zarghooni, M Krengel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 29, 2011
Optimization of hCFTR lung expression in mice using DNA nanoparticlesLinas Padegimas, Tomasz H Kowalczyk, Sam Adams, et al.
HIV Medicine|June 13, 2002
Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapyM Lichterfeld, H D Nischalke, F Bergmann, et al.
HIV Medicine|September 25, 2014
Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort studyC Hoffmann, M Hentrich, D Gillor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2006
Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter studyM Hentrich, L Maretta, K U Chow, et al.
Infection|February 4, 2021
Torque Teno Virus plasma level as novel biomarker of retained immunocompetence in HIV-infected patientsL Schmidt, B-E O Jensen, A Walker, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Klinische Padiatrie|April 8, 2011
Terminally differentiated CD8 cells in HIV-infected children: HIV-GAG/POL specificity and IFN-γ productionD Delbeck, M Siepermann, O Feyen, et al.
AIDS (London, England)|July 14, 2000
Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study GroupJ K Rockstroh, F Bergmann, W Wiesel, et al.
Deutsche Medizinische Wochenschrift (1946)|April 26, 2007
[Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005]M Oette, R Kaiser, M Däumer, et al.
Gene Therapy|March 10, 2006
Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticlesT L Fink, P J Klepcyk, S M Oette, et al.
Spine|May 30, 2009
Treatment of spondylodiscitis in human immunodeficiency virus-infected patients: a comparison of conservative and operative therapyR Sobottke, K Zarghooni, M Krengel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 29, 2011
Optimization of hCFTR lung expression in mice using DNA nanoparticlesLinas Padegimas, Tomasz H Kowalczyk, Sam Adams, et al.
HIV Medicine|June 13, 2002
Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapyM Lichterfeld, H D Nischalke, F Bergmann, et al.
HIV Medicine|September 25, 2014
Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort studyC Hoffmann, M Hentrich, D Gillor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2006
Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter studyM Hentrich, L Maretta, K U Chow, et al.
Infection|February 4, 2021
Torque Teno Virus plasma level as novel biomarker of retained immunocompetence in HIV-infected patientsL Schmidt, B-E O Jensen, A Walker, et al.
Pageof 4